What exactly is TB-500, and how is it characterised in the literature?
TB-500 is a name used in the research-chemical market for material related to thymosin beta 4, a member of the beta-thymosin family of small, ~5 kDa, intrinsically disordered peptides that were first isolated and sequenced decades ago (PMID:4088087, PMID:17468232). Thymosin beta 4 is best known biochemically as a G-actin sequestering peptide; its interactions with monomeric actin are among the most studied features of the molecule (PMID:12852258). Structural surveys of the thymosin family describe the conserved actin-binding motif and the largely unstructured solution conformation that distinguishes these peptides from globular proteins (PMID:27450728). This matters for a buyer because the physicochemical profile — small size, high hydrophilicity, lack of stable tertiary structure — directly shapes which analytical methods are appropriate for confirming identity and purity. From a procurement standpoint, understanding that TB-500 vendor material is characterised against the known thymosin beta 4 sequence lets you check whether a supplier's certificate of analysis reports the expected monoisotopic and average mass, the correct amino-acid content, and a purity value determined by a validated separation. Expression and distribution studies across human tissues further document the peptide's molecular context in the scientific record (PMID:38994967), reinforcing that this is a well-mapped research analyte rather than an obscure compound. None of this literature speaks to any use in people; it is cited here only to establish the analytical reference points a diligent Australian buyer can compare against supplier documentation before purchasing research-grade material.
Where should you buy TB-500 in Australia, and what makes a supplier verifiable?
When deciding where to buy TB-500 in Australia, prioritise suppliers whose verifiability can be independently checked rather than those competing on price alone. A verifiable Australian research supplier will (1) hold local stock and dispatch domestically with tracked shipping, so chain-of-custody is documented from warehouse to laboratory; (2) assign a unique lot number to each batch and make a matching certificate of analysis available; and (3) describe the analytical methods used, not just headline purity numbers. Local dispatch matters practically: an AU-based warehouse with tracked consignment notes gives you a documented transit record and a clear batch reference, which is far more useful for a research audit trail than opaque international parcels. Ask whether the certificate of analysis is lot-specific — a generic, undated PDF reused across every order is a red flag. A credible supplier should be able to state the reversed-phase HPLC conditions, the mass-spectrometry platform used for identity, and the counterion status of the salt form. Because thymosin beta 4-related peptides are extensively described in the scientific literature (PMID:17468232, PMID:27450728), you can cross-reference a supplier's reported mass and sequence against published values. Evaluate the vendor's documentation transparency, its willingness to answer method questions, and whether it publishes batch and quality resources. Our own approach — Australian warehousing, per-lot certificates and tracked dispatch — is designed around exactly these verifiability criteria, all within a research-only framing.
How is TB-500 identity confirmed by mass spectrometry?
Identity confirmation is the single most important documentation item to check before you buy. For a small peptide like thymosin beta 4-related TB-500, electrospray ionisation mass spectrometry (ESI-MS) is the workhorse: the multiply charged ion envelope is deconvoluted to an average or monoisotopic mass, which is then compared with the theoretical value calculated from the published sequence. MALDI-TOF provides an orthogonal, singly charged mass measurement that is useful as an independent confirmation. A rigorous certificate of analysis reports the observed mass, the expected mass, and the mass error (typically expressed in Da or ppm). Because the beta-thymosins are well documented in the literature, the target mass is unambiguous and easily cross-referenced (PMID:17468232, PMID:12852258). Where deeper confirmation is warranted, tandem mass spectrometry (MS/MS) fragments the peptide to generate a b/y-ion series that maps back to the amino-acid sequence, distinguishing the intended peptide from a same-mass impurity or a truncated variant. For a buyer, the key questions are: does the report state the instrument platform, does it give both observed and theoretical mass, and does it include a spectrum or annotated data rather than a bare pass/fail. Structural characterisation reviews of the thymosin family underline how sequence-level confirmation supports unambiguous identity assignment (PMID:27450728). Identity and purity are separate attributes: a correct mass does not guarantee a clean sample, which is why HPLC purity data must accompany the MS identity result on any credible certificate.
What HPLC purity and impurity data should the certificate show?
Purity for TB-500 material is conventionally determined by reversed-phase HPLC with UV detection, and the certificate should specify the column chemistry, mobile-phase gradient, detection wavelength and the resulting main-peak area percentage. Because thymosin beta 4-type peptides are hydrophilic and disordered, method development often uses shallow acetonitrile/water gradients with an ion-pairing modifier to achieve resolution between the target peak and closely eluting related substances. A meaningful report distinguishes the main-peak purity from the related-substances profile: synthetic peptide impurities such as deletion, truncation and deamidation species can co-elute closely and must be resolved and quantified. Peak-purity assessment using diode-array detection (DAD) helps confirm that the main peak represents a single component rather than co-eluting species, using purity-angle and purity-threshold parameters. Look also for the counterion and net-peptide-content information: acetate versus trifluoroacetate salt form affects the true peptide mass fraction, and a stated net peptide content prevents over-reporting of quantity. Orthogonal confirmation strengthens confidence — pairing RP-HPLC purity with an ion-exchange or complementary separation reduces the chance that a co-eluting impurity is missed. When a certificate reports a single purity figure with no method detail, no wavelength and no chromatogram, treat it as insufficient for research decision-making. The extensive characterisation of thymosin beta 4 in the biochemical literature (PMID:12852258, PMID:17468232) provides the reference framework against which such analytical data should be read, purely for identity and purity verification and not for any use claim.
What documentation and batch traceability should accompany an Australian order?
For research procurement, documentation is the deliverable that outlasts the vial. A complete package for TB-500 purchased in Australia should include: a lot-specific certificate of analysis dated and tied to a unique batch number; the identity result (ESI-MS and/or MALDI-TOF observed versus theoretical mass); the HPLC purity result with method parameters and acceptance limits; the counterion and net peptide content; and, where offered, endotoxin or bioburden data relevant to research handling. Batch traceability means each vial can be linked back through the lot number to the analytical records and to the dispatch consignment, forming a continuous audit trail from warehouse to bench. For bulk or multi-vial orders, ask whether a consolidated batch report demonstrates lot uniformity across vials, and whether every vial cross-references the same certificate. Stability and storage guidance should describe the lyophilised form's handling and the reconstituted-solution considerations, again framed strictly around analytical stability rather than any use protocol. Retaining this documentation supports reproducibility: if a downstream assay behaves unexpectedly, a traceable lot and its certificate let you determine whether material identity or purity is a contributing variable. Given that thymosin beta 4 is a heavily referenced analyte across the literature (PMID:38994967, PMID:27450728), aligning your supplier's reported values with published characterisation is straightforward and is the most reliable safeguard when deciding where to buy. A supplier that publishes how to read a certificate of analysis and what a batch test covers is demonstrating the transparency a research buyer should expect.
Order Tb 500 with documentation
If this guide helped you evaluate Tb 500 for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Tb 500 card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Is TB-500 the same as thymosin beta 4?
TB-500 is a research-market name for material related to thymosin beta 4, a well-characterised small actin-binding peptide described extensively in the biochemical literature (PMID:17468232, PMID:12852258). For purchasing purposes, confirm that a supplier's certificate reports the expected thymosin beta 4 mass and sequence rather than relying on the trade name alone.
What documentation should I ask for before buying TB-500 in Australia?
Request a lot-specific certificate of analysis showing mass-spectrometry identity (observed versus theoretical mass), HPLC purity with method parameters, counterion and net peptide content, and a unique batch number that traces to the dispatch record. Generic, undated certificates reused across orders are a red flag.
How is TB-500 identity verified analytically?
Identity is confirmed by mass spectrometry: ESI-MS deconvolutes the charge envelope to a measured mass compared with the theoretical value, and MALDI-TOF or MS/MS provides orthogonal confirmation. The target mass and sequence are well documented for thymosin beta 4 (PMID:27450728, PMID:17468232), so reported values can be cross-referenced.
Why does buying from an Australian supplier matter for research?
Local Australian stock with tracked domestic dispatch provides a documented chain-of-custody and a clear batch reference from warehouse to laboratory. This supports a cleaner audit trail and faster access than opaque international parcels, while per-lot certificates let you verify identity and purity for each order.
What purity information should a TB-500 certificate include?
It should state reversed-phase HPLC main-peak purity along with the column, gradient, detection wavelength and acceptance limit, plus a related-substances profile and, ideally, a peak-purity (DAD) assessment. Counterion and net peptide content should also appear so the true peptide fraction is clear.
References
- PMID:17468232 — beta-Thymosins — Ann N Y Acad Sci — 2007
- PMID:12852258 — Thymosin beta 4 interactions — Vitam Horm — 2003
- PMID:27450728 — Structures of Thymosin Proteins — Vitam Horm — 2016
- PMID:4088087 — Thymosin beta 4 — Methods Enzymol — 1985
- PMID:38994967 — Thymosin β(4) and β(10) Expression in Human Organs during Development: A Review — Cells — 2024
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
